These findings imply NAD+ may be a potential novel therapeutic method in CCH-induced cognitive impairment, and targeting Sirt1/PGC-1α pathway may be a promising treatment strategy in VaD. The gene discussed is SIRT1; the disease is Cognitive impairment.